Furthermore, nivolumab is no longer considered a standard second-line treatment option for patients with metastatic NSCLC, as immunotherapy is now commonly used in the first-line setting based on PD-L1 expression [20]. Here, CD274 is linked to non-small cell lung carcinoma.